Dr. Hari on CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

Parameswaran Hari, MD, MRCP, discusses the use of CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

Parameswaran Hari, MD, MRCP, the Armand J. Quick/William F. Stapp Professor of Hematology, and the chief of the Division of Hematology/Oncology, Department of Medicine, at the Medical College of Wisconsin, discusses the use of CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

Data from the phase Ib/II CARTITUDE-1 trial (NCT03548207), which examined the efficacy of the anti-BCMA CAR T-cell therapy JNJ-68284528 (JNJ-4528) in 29 patients with heavily pretreated relapsed/refractory multiple myeloma, were presented at the 2019 ASH Annual Meeting.

All patients were triple-exposed, meaning that they received a CD38 monoclonal antibody, an immunomodulatory drug, and a proteasome inhibitor, says Hari, with 86% of patients identified as being triple-refractory. Treatment with the product led to an overall response rate of 100%. Specifically, the ORR was comprised of a 66% stringent complete response (CR) rate, a 3% CR rate, a 17% very good partial response (PR) rate, and a 14% PR rate.

It is unknown how long these responses will last or how much this treatment will eventually cost, but for a disease with extremely poor prognosis, BCMA targeting with CAR T-cells remains a wonderful opportunity for development, says Hari.

In fact, these products are expected to move forward into earlier lines of treatment and change the natural history of the disease, concludes Hari.

Related Videos
Binod Dhakal, MD, on Assessing Cilta-Cel in Lenalidomide-Refractory Multiple Myeloma
Brian Van Tine, MD, PhD, on Further Research With Cell Therapy in Synovial Sarcoma
Brian Van Tine, MD, PhD, on Continued Durability of Afami-Cel in Synovial Sarcoma
Thomas McCauley, PhD, on Treating Solid Tumors With Epigenomic Controllers
Rebecca Cottman, PhD, on Creating Regulated Gene Circuits to Enhance Cell Therapy Cytotoxicity
John Leonard, PhD, on an AAV Approach to Exon 51 Skipping in DMD
Joseph Fraietta, PhD, on Investigating Molecular Pathways of CAR T-Cell Resistance
Related Content
© 2023 MJH Life Sciences

All rights reserved.